Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation

Liang Chieh Chen, Hui Ju Tseng, Chang Yi Liu, Yun Yi Huang, Cheng Chung Yen, Jing Ru Weng, Yeh Lin Lu, Wen Chi Hou, Tony E. Lin, I. Horng Pan, Kuo Kuei Huang, Wei Jan Huang, Kai Cheng Hsu

研究成果: 雜誌貢獻文章

摘要

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with multiple etiologies. Beta-amyloid (Aβ) self-aggregation and overexpression of class IIa histone deacetylases (HDACs) are strongly implicated with AD pathogenesis. In this study, a series of novel diarylheptanoid derivatives were designed, synthesized and evaluated for use as dual Aβ self-aggregation and class IIa HDAC inhibitors. Among these compounds, 4j, 5c, and 5e displayed effective inhibitions for Aβ self-aggregation, HDAC5 activity and HDAC7 activity with IC50 values of < 10 μM. The compounds contain three common features: (1) a catechol or pyrogallol moiety, (2) a carbonyl linker and (3) an aromatic ring that can function as an HDAC cap and create hydrophobic interactions with Aβ1-42. Furthermore, compounds 4j, 5c, and 5e showed no significant cytotoxicity to human neuroblastoma SH-SY5Y cells and also exhibited neuroprotective effect against H2O2-induced toxicity. Overall, these promising in vitro data highlighted compounds 4j, 5c, and 5e as lead compounds that are worthy for further investigation.
原文英語
文章編號708
期刊Frontiers in Pharmacology
9
發行號JUL
DOIs
出版狀態已發佈 - 七月 3 2018

指紋

Diarylheptanoids
Histone Deacetylases
Amyloid
Alzheimer Disease
Pyrogallol
Neuroprotective Agents
Neuroblastoma
Hydrophobic and Hydrophilic Interactions
Neurodegenerative Diseases
Inhibitory Concentration 50

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation. / Chen, Liang Chieh; Tseng, Hui Ju; Liu, Chang Yi; Huang, Yun Yi; Yen, Cheng Chung; Weng, Jing Ru; Lu, Yeh Lin; Hou, Wen Chi; Lin, Tony E.; Pan, I. Horng; Huang, Kuo Kuei; Huang, Wei Jan; Hsu, Kai Cheng.

於: Frontiers in Pharmacology, 卷 9, 編號 JUL, 708, 03.07.2018.

研究成果: 雜誌貢獻文章

Chen, Liang Chieh ; Tseng, Hui Ju ; Liu, Chang Yi ; Huang, Yun Yi ; Yen, Cheng Chung ; Weng, Jing Ru ; Lu, Yeh Lin ; Hou, Wen Chi ; Lin, Tony E. ; Pan, I. Horng ; Huang, Kuo Kuei ; Huang, Wei Jan ; Hsu, Kai Cheng. / Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation. 於: Frontiers in Pharmacology. 2018 ; 卷 9, 編號 JUL.
@article{d3adbdc4eeb84a1fb0975530f6ec7187,
title = "Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disorder with multiple etiologies. Beta-amyloid (Aβ) self-aggregation and overexpression of class IIa histone deacetylases (HDACs) are strongly implicated with AD pathogenesis. In this study, a series of novel diarylheptanoid derivatives were designed, synthesized and evaluated for use as dual Aβ self-aggregation and class IIa HDAC inhibitors. Among these compounds, 4j, 5c, and 5e displayed effective inhibitions for Aβ self-aggregation, HDAC5 activity and HDAC7 activity with IC50 values of < 10 μM. The compounds contain three common features: (1) a catechol or pyrogallol moiety, (2) a carbonyl linker and (3) an aromatic ring that can function as an HDAC cap and create hydrophobic interactions with Aβ1-42. Furthermore, compounds 4j, 5c, and 5e showed no significant cytotoxicity to human neuroblastoma SH-SY5Y cells and also exhibited neuroprotective effect against H2O2-induced toxicity. Overall, these promising in vitro data highlighted compounds 4j, 5c, and 5e as lead compounds that are worthy for further investigation.",
keywords = "Alzheimer's disease, Aβ aggregation, Dual inhibitors, Histone deacetylase, Isoform-selective inhibitors",
author = "Chen, {Liang Chieh} and Tseng, {Hui Ju} and Liu, {Chang Yi} and Huang, {Yun Yi} and Yen, {Cheng Chung} and Weng, {Jing Ru} and Lu, {Yeh Lin} and Hou, {Wen Chi} and Lin, {Tony E.} and Pan, {I. Horng} and Huang, {Kuo Kuei} and Huang, {Wei Jan} and Hsu, {Kai Cheng}",
year = "2018",
month = "7",
day = "3",
doi = "10.3389/fphar.2018.00708",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - Design of diarylheptanoid derivatives as dual inhibitors against class IIa histone deacetylase and β-amyloid aggregation

AU - Chen, Liang Chieh

AU - Tseng, Hui Ju

AU - Liu, Chang Yi

AU - Huang, Yun Yi

AU - Yen, Cheng Chung

AU - Weng, Jing Ru

AU - Lu, Yeh Lin

AU - Hou, Wen Chi

AU - Lin, Tony E.

AU - Pan, I. Horng

AU - Huang, Kuo Kuei

AU - Huang, Wei Jan

AU - Hsu, Kai Cheng

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with multiple etiologies. Beta-amyloid (Aβ) self-aggregation and overexpression of class IIa histone deacetylases (HDACs) are strongly implicated with AD pathogenesis. In this study, a series of novel diarylheptanoid derivatives were designed, synthesized and evaluated for use as dual Aβ self-aggregation and class IIa HDAC inhibitors. Among these compounds, 4j, 5c, and 5e displayed effective inhibitions for Aβ self-aggregation, HDAC5 activity and HDAC7 activity with IC50 values of < 10 μM. The compounds contain three common features: (1) a catechol or pyrogallol moiety, (2) a carbonyl linker and (3) an aromatic ring that can function as an HDAC cap and create hydrophobic interactions with Aβ1-42. Furthermore, compounds 4j, 5c, and 5e showed no significant cytotoxicity to human neuroblastoma SH-SY5Y cells and also exhibited neuroprotective effect against H2O2-induced toxicity. Overall, these promising in vitro data highlighted compounds 4j, 5c, and 5e as lead compounds that are worthy for further investigation.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with multiple etiologies. Beta-amyloid (Aβ) self-aggregation and overexpression of class IIa histone deacetylases (HDACs) are strongly implicated with AD pathogenesis. In this study, a series of novel diarylheptanoid derivatives were designed, synthesized and evaluated for use as dual Aβ self-aggregation and class IIa HDAC inhibitors. Among these compounds, 4j, 5c, and 5e displayed effective inhibitions for Aβ self-aggregation, HDAC5 activity and HDAC7 activity with IC50 values of < 10 μM. The compounds contain three common features: (1) a catechol or pyrogallol moiety, (2) a carbonyl linker and (3) an aromatic ring that can function as an HDAC cap and create hydrophobic interactions with Aβ1-42. Furthermore, compounds 4j, 5c, and 5e showed no significant cytotoxicity to human neuroblastoma SH-SY5Y cells and also exhibited neuroprotective effect against H2O2-induced toxicity. Overall, these promising in vitro data highlighted compounds 4j, 5c, and 5e as lead compounds that are worthy for further investigation.

KW - Alzheimer's disease

KW - Aβ aggregation

KW - Dual inhibitors

KW - Histone deacetylase

KW - Isoform-selective inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85049632887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049632887&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00708

DO - 10.3389/fphar.2018.00708

M3 - Article

AN - SCOPUS:85049632887

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUL

M1 - 708

ER -